Locally Advanced Solid Tumor

Oncology·MeSH: Cholangiocarcinoma

14 drugs in development·10 companies·12 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
an2025	Adlai Nortye Ltd. (ANL)

Phase 2(3)

Drug	Company
Cetrelimab	Janux Therapeutics, Inc. (JANX)
rtx-224	Rubius Therapeutics, Inc. (RUBY)
rtx-240	Rubius Therapeutics, Inc. (RUBY)

Phase 1(5)

Drug	Company
amg 436	AMGEN INC (AMGN)
an0025	Adlai Nortye Ltd. (ANL)
CTX-471	Compass Therapeutics, Inc. (CMPX)
NVL-330	Nuvalent, Inc. (NUVL)
PD-L1 t-haNK	ImmunityBio, Inc. (IBRX)

Phase 1/Phase 2(5)

Drug	Company
Neladalkib	Nuvalent, Inc. (NUVL)
oral repotrectinib	TG THERAPEUTICS, INC. (TGTX)
oral repotrectinib	Turning Point Therapeutics, Inc. (TPTX)
TNG462	Tango Therapeutics, Inc. (TNGX)
TNG908	Tango Therapeutics, Inc. (TNGX)

BioSniper tracks 14 drugs in development for Locally Advanced Solid Tumor across 10 companies.

There are 12 clinical trials targeting Locally Advanced Solid Tumor tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.